239 related articles for article (PubMed ID: 27357679)
21. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
22. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
23. GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer.
Su W; Li S; Chen X; Yin L; Ma P; Ma Y; Su B
Oncotarget; 2017 Jan; 8(3):4449-4459. PubMed ID: 27966458
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Anticancer Agents Med Chem; 2021; 21(1):108-119. PubMed ID: 32807067
[TBL] [Abstract][Full Text] [Related]
25. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
26. Lipid pathway deregulation in advanced prostate cancer.
Galbraith L; Leung HY; Ahmad I
Pharmacol Res; 2018 May; 131():177-184. PubMed ID: 29466694
[TBL] [Abstract][Full Text] [Related]
27. AKT and cytosolic phospholipase A2α form a positive loop in prostate cancer cells.
Hua S; Vignarajan S; Yao M; Xie C; Sved P; Dong Q
Curr Cancer Drug Targets; 2015; 15(9):781-91. PubMed ID: 26143945
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury-induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator-activated receptor gamma.
Zeng XC; Li L; Wen H; Bi Q
Mol Med Rep; 2016 Jul; 14(1):129-36. PubMed ID: 27150726
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Managlia E; Katzman RB; Brown JB; Barrett TA
Inflamm Bowel Dis; 2013 Sep; 19(10):2051-60. PubMed ID: 23867870
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis induction in human prostate cancer cells related to the fatty acid metabolism by wogonin-mediated regulation of the AKT-SREBP1-FASN signaling network.
Sun Y; Guo W; Guo Y; Lin Z; Wang D; Guo Q; Zhou Y
Food Chem Toxicol; 2022 Nov; 169():113450. PubMed ID: 36208653
[TBL] [Abstract][Full Text] [Related]
31. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
32. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.
Beckham TH; Cheng JC; Lu P; Marrison ST; Norris JS; Liu X
PLoS One; 2013; 8(10):e76593. PubMed ID: 24098536
[TBL] [Abstract][Full Text] [Related]
33. A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.
Singh KB; Hahm ER; Kim SH; Wendell SG; Singh SV
Oncogene; 2021 Jan; 40(3):592-602. PubMed ID: 33199826
[TBL] [Abstract][Full Text] [Related]
34. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
Dubrovska A; Kim S; Salamone RJ; Walker JR; Maira SM; García-Echeverría C; Schultz PG; Reddy VA
Proc Natl Acad Sci U S A; 2009 Jan; 106(1):268-73. PubMed ID: 19116269
[TBL] [Abstract][Full Text] [Related]
35. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.
Hu Y; Sun H; Owens RT; Wu J; Chen YQ; Berquin IM; Perry D; O'Flaherty JT; Edwards IJ
Neoplasia; 2009 Oct; 11(10):1042-53. PubMed ID: 19794963
[TBL] [Abstract][Full Text] [Related]
36. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.
Chang L; Wu P; Senthilkumar R; Tian X; Liu H; Shen X; Tao Z; Huang P
J Cancer Res Clin Oncol; 2016 Jan; 142(1):59-72. PubMed ID: 26109148
[TBL] [Abstract][Full Text] [Related]
37. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.
Yue S; Li J; Lee SY; Lee HJ; Shao T; Song B; Cheng L; Masterson TA; Liu X; Ratliff TL; Cheng JX
Cell Metab; 2014 Mar; 19(3):393-406. PubMed ID: 24606897
[TBL] [Abstract][Full Text] [Related]
38. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
39. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
40. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.
Su B; Gao L; Baranowski C; Gillard B; Wang J; Ransom R; Ko HK; Gelman IH
PLoS One; 2014; 9(7):e101411. PubMed ID: 24983969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
